{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-039488","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-08-20T20:45:25+00:00","discovered_at":"2026-08-20T20:46:00.269211+00:00","generated_at":"2026-08-20T20:46:03.189435+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Hepion Pharmaceuticals appoints James Liddy as director effective August 19, 2026","bullets":["Board approved James Liddy as director on August 19, 2026, effective immediately.","No arrangements or understandings exist with any person regarding Liddy's selection.","No transactions involving Hepion and Liddy required under Item 404(a) of Reg S-K.","Form signed by interim CEO Gary Stetz on August 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-039488","json":"https://secwatch.observer/filing/0001493152-26-039488.json","markdown":"https://secwatch.observer/filing/0001493152-26-039488.md","text":"https://secwatch.observer/filing/0001493152-26-039488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/0001493152-26-039488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T20:46:03.189435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}